Table 1.
Infliximab pharmacokinetic parameters estimated by a population approach.
| Study | Disease | Patients (n) | Compartments (n) | Vss (L) | CL (L/day) | t1/2 (days) |
|---|---|---|---|---|---|---|
| Ternant 20067 | CD | 6 | 1 | 3 | 0.20 | 10.9 |
| Ternant 20088 | IBD | 33 | 2 | 5.50 | 0.29 | 20.3 |
| Fasanmade 20099 | UC | 482 | 2 | 7.30 | 0.38 | 13.4 |
| Fasanmade 201110 | CD | 692 | 2 | 4.90 | 0.38 | 11.5 |
| Ternant 201411 | CD | 111 | 1 | 5.80 | 0.29 | 14.0 |
| Dotan 201412 | IBD | 54 | 2 | 3.80 | 0.38 | 12.0 |
| Aubourg 201513 | CD | 133 | 2 | 7.10 | 0.34 | 15.7 |
| Present study | IBD | 79 | 1 | 7.95 | 0.35 | 15.5 |
| Xu, 20085 | AS | 274 | 2 | 6.00 | 0.27 | 15.8 |
| Ternant 20116 | AS | 25 | 2 | 4.10 | 0.21 | 13.8 |
| Present study | AS + PsA | 121 | 1 | 5.43 | 0.24 | 15.7 |
| Ternant 20144 | RA | 84 | 2 | 5.90 | 0.32 | 9.0* |
| Present study | RA | 18 | 1 | 5.43 | 0.30 | 10.5* |
Abbreviations are as follows: Vss, volume steady-state; CL, elimination clearance; t1/2, terminal elimination half-life; IBD; inflammatory bowel disease; AS, ankylosing spondylitis; PsA; psoriatic arthritis; RA, rheumatoid arthritis; CD, Crohn's disease; UC, ulcerative colitis.
*
without methotrexate cotreatment.